| Autor: |
Reynaria Pitts, Elise Gunzburger, Christie M. Ballantyne, Philip J. Barter, David Kallend, Lawrence A. Leiter, Eran Leitersdorf, Stephen J. Nicholls, Prediman K. Shah, Jean‐Claude Tardif, Anders G. Olsson, John J. V. McMurray, John Kittelson, Gregory G. Schwartz |
| Jazyk: |
angličtina |
| Rok vydání: |
2017 |
| Předmět: |
|
| Zdroj: |
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 1 (2017) |
| Druh dokumentu: |
article |
| ISSN: |
2047-9980 |
| DOI: |
10.1161/JAHA.116.004119 |
| Popis: |
BackgroundAldosterone may have adverse effects in the myocardium and vasculature. Treatment with an aldosterone antagonist reduces cardiovascular risk in patients with acute myocardial infarction complicated by heart failure (HF) and left ventricular systolic dysfunction. However, most patients with acute coronary syndrome do not have advanced HF. Among such patients, it is unknown whether aldosterone predicts cardiovascular risk. Methods and ResultsTo address this question, we examined data from the dal‐OUTCOMES trial that compared the cholesteryl ester transfer protein inhibitor dalcetrapib with placebo, beginning 4 to 12 weeks after an index acute coronary syndrome. Patients with New York Heart Association class II (with LVEF |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text